---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018410"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:13:08.446758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC

## Summary
- Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.
- Net loss of $19.1M vs $18.3M YoY; R&D expenses increased to $24.6M from $18.3M.
- Cash and equivalents $108.1M as of Sep 30, 2023, down from $113.4M at Dec 31, 2022.
- HB-200 + pembro achieved 42% ORR in 19 evaluable CPI-naïve patients, doubling historical 19% for pembro alone.
- Anticipated milestones: Phase 2 HB-200 data H1 2024, randomized trial mid-2024; IND filings for HB-700 (H1 2024) and HB-500 (Q4 2023).

## SEC filing metadata
- accession: 0001558370-23-018410
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/0001558370-23-018410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/hook-20231109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018410
- JSON: https://secwatch.observer/filing/0001558370-23-018410.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018410.txt

## Key facts
- Earnings Releases
  HOOKIPA Pharma Inc. reported third quarter of 2023 results: revenue $6.9 million, net income $19.1 million.
  - Period: third quarter of 2023
  - Revenue: $6.9 million
  - Net income: $19.1 million
  - Result: reported results
  source text: The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023. ​ Revenue: Revenue was $6.9 million for the three months ended September 30, 2023 and $2.2 million for the three months ended September 30, 2022. This increase was primarily due to higher partial recognition of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/0001558370-23-018410-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.